Skip to main content

Gilead Sciences stock price and financials

  • GILD · Nasdaq
  • Biotechnology
  • S&P 500
$168.08+0.08%Close 13 Nov 2026
Market value
$210.2B
EV / EBITDA
505.27
Dividend yield
2.0%
Beta · 1 year
0.37
Return · 1 year
+36.2%
52-week range$116.88 — $176.58

Share price close 16 Nov 2026

+7.5%1 monthHigh $174.48Low $153.07
$150$160$170$180Q3 FY2026 report filed 30 Oct 202623 Oct29 Oct4 Nov10 Nov16 Nov
+30.6%6 monthsHigh $174.48Low $121.48
$120$140$160$180Q2 FY2026 report filed 6 Aug 2026Q3 FY2026 report filed 30 Oct 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+37.9%year to dateHigh $174.48Low $118.30
$100$120$140$160$180Q4 FY2025 report filed 24 Feb 2026Q1 FY2026 report filed 7 May 2026Q2 FY2026 report filed 6 Aug 2026Q3 FY2026 report filed 30 Oct 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+35.4%1 yearHigh $174.48Low $118.30
$100$120$140$160$180Q4 FY2025 report filed 24 Feb 2026Q1 FY2026 report filed 7 May 2026Q2 FY2026 report filed 6 Aug 2026Q3 FY2026 report filed 30 Oct 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+125%3 yearsHigh $174.48Low $63.15
$50$100$150$200Q4 FY2023 report filed 23 Feb 2024Q1 FY2024 report filed 8 May 2024Q2 FY2024 report filed 8 Aug 2024Q3 FY2024 report filed 12 Nov 2024Q4 FY2024 report filed 28 Feb 2025Q1 FY2025 report filed 7 May 2025Q2 FY2025 report filed 7 Aug 2025Q3 FY2025 report filed 7 Nov 2025Q4 FY2025 report filed 24 Feb 2026Q1 FY2026 report filed 7 May 2026Q2 FY2026 report filed 6 Aug 2026Q3 FY2026 report filed 30 Oct 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+127%10 yearsHigh $174.48Low $57.07
$50$100$150$200Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Gilead Sciences reported revenue of $29.4 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 2.4% from fiscal 2024. Net income was $8.51 billion and diluted earnings per share $6.78.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $8.30 billion, up 6.8% from a year earlier.

Figures from Gilead Sciences's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 30 Oct 2026.

Against Health Care

Growth
Bottom quarter
Revenue +3.6% a year over five years · 29th of 37
Profitability
Upper half
Return on invested capital 12.0%, five-year average · 15th of 38
Balance sheet
Bottom quarter
Net debt 43.8× EBITDA · 38th of 38

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$29.44B+2.4%
Net income
$8.51B+1673%
Diluted EPS
$6.78+1684%
Gross margin
78.8%+0.6 pts
Free cash flow
$9.46B−8.2%
Net debt
$17.91B+3.3%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$10B$20B$30B$40BRevenue, FY16: $30.39BNet income, FY16: $13.5BFY16Revenue, FY17: $26.11BNet income, FY17: $4.63BFY17Revenue, FY18: $22.13BNet income, FY18: $5.46BFY18Revenue, FY19: $22.45BNet income, FY19: $5.39BFY19Revenue, FY20: $24.69BNet income, FY20: $123MFY20Revenue, FY21: $27.3BNet income, FY21: $6.22BFY21Revenue, FY22: $27.28BNet income, FY22: $4.59BFY22Revenue, FY23: $27.12BNet income, FY23: $5.67BFY23Revenue, FY24: $28.75BNet income, FY24: $480MFY24Revenue, FY25: $29.44BNet income, FY25: $8.51BFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 30 Oct 2026 · Full results →

Revenue
$8.30B+6.8% on a year
Gross margin
81.1%+1.3 pts on a year
Operating income
$3.46B+4.1% on a year
Net income
$2.43B−20.4% on a year
Diluted EPS
$1.94−20.2% on a year
Free cash flow
$4.80B+21.1% on a year

Comparable companies All of Health Care →

Gilead Sciences beside the other S&P 500 members in Biotechnology, by market value.

Gilead Sciences and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
Gilead SciencesGILD$210.2B+0.1%+36.2%+6.5%−12.5%—
AbbVieABBV$525.9B+0.2%+26.5%+10.7%15.7%51.1
AmgenAMGN$253.8B−0.3%+38.5%+8.2%24.1%27.0
BiogenBIIB$37.52B+1.2%+56.9%+2.3%3.4%108.0
IncyteINCY$24.67B−0.6%+11.7%+24.9%6.7%61.2
ModernaMRNA—−3.4%+736%———
Regeneron PharmaceuticalsREGN—+0.4%+40.2%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%50%100%78.8%34.0%28.9%FY16FY19FY22FY25

Gilead Sciences revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By product

Gilead Sciences revenue by product, by fiscal year
RevenueFY 2024FY 2025
Biktarvy$13.42B$14.33B+6.8%
Total Liver Disease$3.02B$3.22B+6.5%
Descovy$2.11B$2.76B+30.5%
Total Cell Therapy—$1.84B
Genvoya$1.76B$1.50B−15.0%
Trodelvy$1.31B$1.40B+6.2%
Sofosbuvir/Velpatasvir$1.60B$1.27B−20.3%
Odefsey$1.29B$1.17B−9.4%
Vemlidy$959.0M$1.07B+11.6%
Veklury$1.80B$911.0M−49.4%
Total revenue$28.75B$29.44B

By region

Gilead Sciences revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$19.27B$18.88B−2.0%$19.44B+2.9%$20.59B+5.9%$20.88B+1.4%
Europe$4.87B$4.47B−8.3%$4.31B−3.6%$4.63B+7.5%$5.06B+9.3%
Rest of World$3.16B$3.93B+24.1%$3.37B−14.3%$3.53B+4.8%$3.50B−0.7%
Total revenue$27.30B$27.28B$27.12B$28.75B$29.44B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Gilead Sciences income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$30.39B$26.11B$22.13B$22.45B$24.69B$27.30B$27.28B$27.12B$28.75B$29.44B
Revenue growth−6.9%−14.1%−15.2%+1.5%+10.0%+10.6%−0.1%−0.6%+6.0%+2.4%
Gross profit$26.13B$21.74B$17.27B$17.77B$20.12B$20.70B$21.62B$20.62B$22.50B$23.21B
Operating income$17.63B$14.12B$8.20B$4.29B$4.07B$9.92B$7.33B$7.61B$1.66B$10.02B
Net income$13.50B$4.63B$5.46B$5.39B$123.0M$6.22B$4.59B$5.67B$480.0M$8.51B
Diluted EPS$9.94$3.51$4.17$4.22$0.10$4.93$3.64$4.50$0.38$6.78
Gross margin86.0%83.3%78.1%79.2%81.5%75.8%79.3%76.0%78.3%78.8%
Operating margin58.0%54.1%37.1%19.1%16.5%36.3%26.9%28.0%5.8%34.0%
Net margin44.4%17.7%24.7%24.0%0.5%22.8%16.8%20.9%1.7%28.9%

Cash flow

Gilead Sciences cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$17.05B$11.90B$8.40B$9.14B$8.17B$11.38B$9.07B$8.01B$10.83B$10.02B
Capital expenditure$748.0M$590.0M$924.0M$825.0M$650.0M$579.0M$728.0M$585.0M$523.0M$563.0M
Free cash flow$16.30B$11.31B$7.48B$8.32B$7.52B$10.80B$8.34B$7.42B$10.30B$9.46B

Balance sheet and shares

Gilead Sciences balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$8.23B$7.59B$17.94B$11.63B$6.00B$5.34B$5.41B$6.08B$9.99B$7.56B
Total debt$26.35B$33.54B$27.32B$25.32B$32.12B$27.29B$25.81B$25.66B$27.32B$25.54B
Shareholders' equity$18.89B$20.44B$21.39B$22.52B$18.20B$21.07B$21.24B$22.83B$19.33B$22.70B
Diluted shares1.4B1.3B1.3B1.3B1.3B1.3B1.3B1.3B1.3B1.3B
Dividends per share$1.84$2.08$2.28$2.52$2.72$2.84$2.92$3.00$3.08$3.16

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Gilead Sciences quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$7.57B$6.67B$7.08B$7.77B$7.92B$6.96B$7.80B$8.30B
Revenue, year on year+6.4%−0.3%+1.8%+3.0%+4.7%+4.4%+10.2%+6.8%
Gross margin79.1%76.9%78.8%79.8%79.5%79.2%79.8%81.1%
Operating income$2.45B$2.24B$2.47B$3.33B$1.98B$2.59B−$10.39B$3.46B
Net income$1.78B$1.31B$1.96B$3.05B$2.18B$2.02B−$10.50B$2.43B
Diluted EPS$1.39$1.04$1.56$2.43$1.74$1.61−$8.45$1.94
Free cash flow$2.83B$1.65B$720.0M$3.96B$3.12B$2.43B$3.43B$4.80B

Operating KPIs

The operating figures Gilead Sciences reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Gilead Sciences operating KPIs
KPILatestPeriodChange on a yearRecent periods
Product sales$8.3Bquarter to 30 Sep 2026up 12.9%
Biktarvy revenue$4.1Bquarter to 30 Sep 2026up 10.1%
Descovy revenue$1.0Bquarter to 30 Sep 2026up 49.2%
Trodelvy revenue$506.0Mquarter to 30 Sep 2026up 41.7%
Genvoya revenue$339.0Mquarter to 30 Sep 2026down 10.1%
Vemlidy revenue$333.0Mquarter to 30 Sep 2026up 18.9%
Yeztugo revenue$305.0Mquarter to 30 Sep 2026up 682.1%
Yescarta revenue$294.0Mquarter to 30 Sep 2026down 15.8%
Odefsey revenue$286.0Mquarter to 30 Sep 2026up 3.2%
Sofosbuvir/Velpatasvir revenue$274.0Mquarter to 30 Sep 2026down 11.3%
Livdelzi revenue$203.0Mquarter to 30 Sep 2026up 93.3%
Symtuza - Revenue share revenue$132.0Mquarter to 30 Sep 2026up 6.5%
AmBisome revenue$99.0Mquarter to 30 Sep 2026down 19.5%
Veklury revenue$86.0Mquarter to 30 Sep 2026down 69.0%
Tecartus revenue$60.0Mquarter to 30 Sep 2026down 27.7%
Royalty, contract and other revenues$11.0Mquarter to 30 Sep 2026down 97.4%
United States revenue$6.4Bquarter to 30 Sep 2026up 20.5%
Europe revenue$1.1Bquarter to 30 Sep 2026down 31.5%
Rest of World revenue$872.0Mquarter to 30 Sep 2026down 6.5%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Gilead Sciences's revenue in fiscal 2025?

$29.4 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Gilead Sciences's net income in fiscal 2025?

$8.51 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Gilead Sciences's diluted earnings per share in fiscal 2025?

$6.78 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Gilead Sciences's gross margin?

78.8% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Gilead Sciences's operating margin?

34.0% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Gilead Sciences generate in fiscal 2025?

$9.46 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Gilead Sciences's revenue come from?

In fiscal 2025, by product: Biktarvy $14.33B (49%), Total Liver Disease $3.22B (11%), Descovy $2.76B (9.4%), Total Cell Therapy $1.84B (6.2%), out of $29.44B in all, as stated in its annual report.

In the terminal

Twenty years of Gilead Sciences's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans